R&D News | pharmaphorum

News

Nanoscope gene therapy clears ph2 retinitis pigmentosa trial

Nanoscope Therapeutics has reported data from a mid-stage clinical trial that suggests its optogenetic therapy based on light-sensitive molecules is an effective treatment

News

Clinical trial go-between Inato raises $20m

Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t

News

GSK boosts anti-infectives pipeline with Scynexis antifungal

Last year, GSK said it was planning to invest a cool £1 billion in infectious d

News

J&J decides not to play catch-up in RSV vaccination

Johnson & Johnson has decided to bow out of the market for respiratory syncytial virus (RSV) vaccines, abandoning a late-stage development programme that would have be

News

GSK, Merck in endometrial cancer face-off

GSK and Merck & Co have both reported new clinical data with the PD-1 checkpoint inhibitors, seeking an edge in the first-line treatment of advanced endometrial cancer

News

BMS upgrades Evotec neurology alliance, now worth up to $4bn

Bristol-Myers Squibb has expanded a long-running alliance with Evotec once again, paying another $50 million upfront to deepen their collaboration on drugs to treat neurod

Nanoscope gene therapy clears ph2 retinitis pigmentosa trial

Clinical trial go-between Inato raises $20m

GSK boosts anti-infectives pipeline with Scynexis antifungal

J&J decides not to play catch-up in RSV vaccination

GSK, Merck in endometrial cancer face-off

BMS upgrades Evotec neurology alliance, now worth up to $4bn

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks